Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution | Zendy

Roman S. Kozlov | Zendy; A. I. Sinopalnikov | Zendy; О В Зайцева | Zendy; S. К. Zyryanov | Zendy; Е. П. Карпова | Zendy; E.Yu. Radzig | Zendy; С. В. Зайцева | Zendy; Э. Э. Локшина | Zendy; Olga Ulianovna Stetsyuk | Zendy; Irina V. Andreeva | Zendy

Open Access

Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution

Author(s) -

Roman S. Kozlov,

A. I. Sinopalnikov,

О В Зайцева,

S. К. Zyryanov,

Е. П. Карпова,

E.Yu. Radzig,

С. В. Зайцева,

Э. Э. Локшина,

Olga Ulianovna Stetsyuk,

Irina V. Andreeva

Publication year - 2021

Publication title -

clinical review for general practice

Language(s) - English

Resource type - Journals

eISSN - 2782-5671

pISSN - 2713-2552

DOI - 10.47407/kr2021.2.1.00036

Subject(s) - amoxicillin , medicine , respiratory tract infections , antimicrobial , intensive care medicine , respiratory system , antibiotics , biology , microbiology and biotechnology

The meeting of Expert Council, which included representatives of leading Russian research and higher education medical institutions, took place in Moscow. The Council discussed approaches to therapy of respiratory tract infections and ENT infections in children considering the global increase in antimicrobial resistance of respiratory tract pathogens. Special attention was paid to the use of new dosage form of amoxicillin-clavulanate 14:1, as well as to defining the category of patients to whom it is advisable to prescribe the high-dose amoxicillin-clavulanate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research